Results

1–8 of 8 results for Diana V Do

Expert Panel: Faricimab and Aflibercept 8 mg in Diabetic Retinopathy
Judy E. Kim, MD, FASRS
Chirag D. Jhaveri, MD, FASRS
Michael S. Ip, MD
Arshad M. Khanani, MD, MA, FASRS
Jordana G Fein, MD, MS
Dennis M. Marcus, MD
Diana V Do, MD, FASRS
Annual Meeting Talks
2024
Clinical Utility of the Fellow Eye in Patients With Bilateral GA Due to AMD: Long-Term Data from the Pegcetacoplan Clinical Program
Diana V Do, MD, FASRS
Updates from the Field
2025
Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial
Diana V Do, MD, FASRS
Updates from the Field
2024
Association Between DRSS Changes and Visual/ Anatomic Outcomes in Patients With Moderately Severe to Severe NPDR: Post Hoc Analysis of PANORAMA
Diana V Do, MD, FASRS
Annual Meeting Talks
2022
Comparative Efficacy of Different Anti-VEGF Treatment Regimens in Patients With nAMD: A Network Meta-Analysis
Diana V Do, MD, FASRS
Annual Meeting Talks
2020
Vision Threatening Complications in Patients With Diabetic Macular Edema: A Post Hoc Analysis of the VISTA and VIVID Trials
Diana V Do, MD, FASRS
Updates from the Field
2019
Vision Threatening Complications in Patients With Diabetic Macular Edema: A Post Hoc Analysis of the VISTA and VIVID Trials
Diana V Do, MD, FASRS
Annual Meeting Talks
2019
Regression of Diabetic Retinopathy with Anti-VEGF Treatment: What is Learned from a Meta-Analysis of Four Pivotal Clinica
Diana V Do, MD, FASRS
Updates from the Field
2019